2 Biotech Firms Hope To Tap Thawing IPO Market For $495M
Brain disease-focused Neumora Therapeutics Inc. and radiopharmaceutical-drug maker RayzeBio Inc. launched plans on Monday for initial public offerings that could raise a combined $495 million under the guidance of three law...To view the full article, register now.
Already a subscriber? Click here to view full article